Last reviewed 2026-04-20 · How we verify

Mozobil (plerixafor)

Mozobil works by binding to the C-C chemokine receptor type 2, which helps to mobilize hematopoietic stem cells from the bone marrow into the bloodstream.

At a glance

Mechanism of action

Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1 (SDF-1). SDF-1 and CXCR4 are recognized to play role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1 or through the induction of other adhesion molecules. Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable of engraftment with long-term repopulating capacity up to one year in canine transplantation models.

Approved indications

• Malignant lymphoma
• Multiple myeloma
• Peripheral Mobilization of Hematopoietic Stem Cells
• Solid malignant tumours

Common side effects

• Diarrhea
• Nausea
• Fatigue
• Injection site reactions
• Headache
• Arthralgia
• Dizziness
• Vomiting
• Flatulence
• Hyperleukocytosis
• Gastrointestinal disorders
• General disorders and administration site conditions

Key clinical trials

• Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients (PHASE3)
• Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients (PHASE3)
• A Phase I Study of Mozobil in the Treatment of Patients With WHIMS (PHASE1,PHASE2)
• Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models (PHASE2)
• Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (PHASE1,PHASE2)
• Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia (PHASE1,PHASE2)
• Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (PHASE1,PHASE2)
• CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.